Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

Update Il y a 5 ans
Reference: NCT00900614

Woman and Man

  • | Country :
  • Sweden
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.


Inclusion criteria

  • Hematologic Neoplasms ,Prostatic Neoplasms

Links